View in EDS

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.

Saved in:

Bibliographic Details
Title:	A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.
Authors:	Tolcher AW; South Texas Accelerated Research Therapeutics LLC, San Antonio. Electronic address: atolcher@start.stoh.com., Bendell JC; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville., Papadopoulos KP; South Texas Accelerated Research Therapeutics LLC, San Antonio., Burris HA 3rd; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville., Patnaik A; South Texas Accelerated Research Therapeutics LLC, San Antonio., Jones SF; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville., Rasco D; South Texas Accelerated Research Therapeutics LLC, San Antonio., Cox DS; GlaxoSmithKline, Collegeville., Durante M; GlaxoSmithKline, Collegeville., Bellew KM; Pharmaceutical Companies of Johnson and Johnson, Greater Philadelphia Area., Park J; GlaxoSmithKline, Collegeville., Le NT; Novartis, East Hanover, USA., Infante JR; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville.
Source:	Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2015 Jan; Vol. 26 (1), pp. 58-64. Date of Electronic Publication: 2014 Oct 24.
Publication Type:	Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1569-8041
DOI:	10.1093/annonc/mdu482